Neurosense Therapeutics is trading 10.49% down at $1.28; no clear company-specific catalyst was identified for November 3.
- Following a sharp November 2 decline, H.C. Wainwright downgraded it to Neutral from Buy; PrimeC’s planned Health Canada filing shifted from December 2026 to March 2027. Neither establishes current cause.
- Biotech shares are higher; XBI is up 2.13%, so sector weakness does not explain the decline.
- Nasdaq reported 3,320,360 shares at 10:23 a.m. ET; that snapshot does not establish full-day activity.